Tasigna — Blue Cross Blue Shield of Illinois
newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase
Preferred products
- imatinib (generic)
- dasatinib (generic)
Initial criteria
- Patient must meet ALL general initial evaluation criteria
- Requested agent is non-preferred for specified indication; approval requires ONE of the following: current stable use; failure, intolerance, contraindication, or non-effectiveness of ONE preferred agent (imatinib (generic) or dasatinib (generic)); previous treatment with Bosulif or Tasigna for CML